- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20:50 | Multi-channel sales strategy drives growth for tissue repair biotech Aroa | 1 | Stockhead | ||
| 25.11. | Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26 | 1 | smallcaps.com.au | ||
| 25.11. | Health Check: It's quarterly report 'Liberation Day' for Aroa after a bumper first half result | 1 | Stockhead | ||
| 24.11. | AROA BIOSURGERY LIMITED: Aroa Half Year Results Presentation | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 24.11. | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 FY26 Results | - | ASX | ||
| 24.11. | AROA BIOSURGERY LIMITED: Appendix 4D and Half Year Report | - | ASX | ||
| 12.11. | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | 2 | ASX | ||
| 11.11. | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 Results Webinar & Investor Event | - | ASX | ||
| 03.11. | AROA BIOSURGERY LIMITED: Initial Director's Interest Notice - PS | - | ASX | ||
| 03.11. | AROA BIOSURGERY LIMITED: Final Director's Interest Notice - JP | - | ASX | ||
| 31.10. | AROA BIOSURGERY LIMITED: Paul Shearer to join Aroa Board and John Pinion to Retire | 1 | ASX | ||
| 15.10. | AROA BIOSURGERY LIMITED: Investor Presentation | - | ASX | ||
| 15.10. | AROA BIOSURGERY LIMITED: September 2025 Quarterly Report and Appendix 4C | - | ASX | ||
| 10.10. | AROA BIOSURGERY LIMITED: Change in substantial holding | 1 | ASX | ||
| 09.10. | AROA BIOSURGERY LIMITED: Notification of Quarterly Results Webinar | 1 | ASX | ||
| 08.10. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 23.09. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - BW | - | ASX | ||
| 23.09. | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | - | ASX | ||
| 10.09. | Aroa to hit right note as US skin substitute rules set for change | 1 | Stockhead | ||
| 20.08. | AROA BIOSURGERY LIMITED: Results of Annual General Meeting | - | ASX |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,00 | -0,64 % | 60 Prozent Aufwärtspotenzial?: BioNTech: Diese Gamechanger sind noch nicht im Kurs eingepreist! | © Foto: Sebastian Gollnow/dpa Für Anleger von BioNTech gab es 2025 nicht viel zu feiern. Auf Jahressicht hat die Aktie rund 15 Prozent verloren. Dabei sind die großen Innovationen im Krebsbereich noch... ► Artikel lesen | |
| EVOTEC | 5,170 | -0,77 % | Evotec Aktie: Finaler Selloff? | Dass Evotecs langjähriger Ankeraktionär Novo Holdings aussteigen will, wie Bloomberg berichtet, hat die Biotech-Aktie gestern deutlich unter Druck gebracht. Intraday fiel das TecDAX-Papier auf ein neues... ► Artikel lesen | |
| CUREVAC | 3,538 | -13,58 % | EILMELDUNG: Curevac unter Druck - Anleger verlieren die Nerven! | ||
| MODERNA | 25,980 | +2,12 % | Moderna, Inc.: Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference | CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30... ► Artikel lesen | |
| NOVAVAX | 5,670 | +1,78 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| HEIDELBERG PHARMA | 2,610 | +1,16 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,240 | +13,13 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| DYNAVAX | 9,210 | +0,22 % | Dynavax Technologies: Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program | HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 44,210 | +0,32 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| VAXART | 0,301 | +7,12 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| IBIO | 1,730 | -2,26 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,880 | -0,61 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| CELLECTAR BIOSCIENCES | 2,800 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.